Skip Nav Destination
Issues
1 January 2012
-
Cover Image
Cover Image
Epithelial ovarian carcinoma is the deadliest gynecologic cancer. Immunohistochemistry showed that a chemokine receptor fractalkine (CX3CR1) is expressed in human specimens of ovarian carcinoma. The soluble form of chemokine fractalkine (CX3CL1) was present in the ascites fluid of ovarian carcinoma patients, and its membrane-inserted form was expressed by peritoneal mesothelial cells. Functionally, the interaction between CX3CR1 and CX3CL1 induced adhesion of ovarian carcinoma cells to the mesothelial monolayer, facilitated cell migration, and enhanced proliferation. For further details, please see the article by Kim and coworkers on page 11 in this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1541-7786
EISSN 1557-3125
Journal Archive
Molecular Cancer Research (2002-Present; volumes 1-current)
(ISSN 0008-5472) Published monthly since November, 2002.Cell Growth & Differentiation (1990-2002; volumes 1-13)
(ISSN 1044-9523) Published monthly 1990- September, 2002.Table of Contents
Highlights
Angiogenesis, Metastasis, and the Cellular Microenvironment
Cancer Genes and Genomics
STEAP1 Is Associated with the Invasive and Oxidative Stress Phenotype of Ewing Tumors
Thomas G.P. Grunewald; Isabel Diebold; Irene Esposito; Stephanie Plehm; Kristina Hauer; Uwe Thiel; Patricia da Silva-Buttkus; Frauke Neff; Rebekka Unland; Carsten Müller-Tidow; Colette Zobywalski; Katharina Lohrig; Urs Lewandrowski; Albert Sickmann; Olivia Prazeres da Costa; Agnes Görlach; Andrea Cossarizza; Elke Butt; Günther H.S. Richter; Stefan Burdach
Cell Cycle, Cell Death, and Senescence
DNA Damage and Cellular Stress Responses
Signaling and Regulation
The Oncogenic RNA-Binding Protein Musashi1 Is Regulated by HuR via mRNA Translation and Stability in Glioblastoma Cells
Dat T. Vo; Kotb Abdelmohsen; Jennifer L. Martindale; Mei Qiao; Kumiko Tominaga; Tarea L. Burton; Jonathan A.L. Gelfond; Andrew J. Brenner; Vyomesh Patel; Daniel Trageser; Björn Scheffler; Myriam Gorospe; Luiz O.F. Penalva
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.